On Jul. 29, 2020, Veracyte and MAVIDx announced an agreement for MAVIDx to develop ultra-high throughput genomic testing for SARS-CoV-2, the virus that causes COVID-19, on the nCounterﾮ Analysis System, Veracyteﾒs diagnostics platform.

The agreement is intended to enable diagnostic testing and population screening for COVID-19 at an unprecedented scale ﾖ up to 40,000 samples per day performed on the easy-to-use nCounter instrument ﾖ through technology that attaches molecular barcodes to individual RNA molecules of the virus.